Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Hepatology (Baltimore, Md.)|January 8, 2019
Integrative Analysis Defines Distinct Prognostic Subgroups of Intrahepatic CholangiocarcinomaBenjamin Goeppert, Reka Toth, Stephan Singer, et al.
Genes, Chromosomes & Cancer|July 21, 2016
Tubular, lactating, and ductal adenomas are devoid of MED12 Exon2 mutations, and ductal adenomas show recurrent mutations in GNAS and the PI3K-AKT pathwayAnna-Lena Volckmar, Jonas Leichsenring, Christa Flechtenmacher, et al.
Cold Spring Harbor Molecular Case Studies|November 23, 2019
Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1-ALK-rearranged lung cancerSteffen Dietz, Petros Christopoulos, Lisa Gu, et al.
Cancers|September 8, 2019
RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer SamplesMartina Kirchner, Olaf Neumann, Anna-Lena Volckmar, et al.
Oncoimmunology|April 14, 2017
PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcomaJan Budczies, Gunhild Mechtersheimer, Carsten Denkert, et al.
Virchows Archiv : an International Journal of Pathology|March 23, 2016
NGS-based BRCA1/2 mutation testing of high-grade serous ovarian cancer tissue: results and conclusions of the first international round robin trialVolker Endris, Albrecht Stenzinger, Nicole Pfarr, et al.
Blood|January 26, 2017
Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemiaTilmann Bochtler, Martin Granzow, Friedrich Stölzel, et al.
Virchows Archiv : an International Journal of Pathology|September 9, 2017
EGFR T790M mutation testing of non-small cell lung cancer tissue and blood samples artificially spiked with circulating cell-free tumor DNA: results of a round robin trialJana Fassunke, Michaela Angelika Ihle, Dido Lenze, et al.
Cancer Immunology, Immunotherapy : CII|September 25, 2019
The BRCA2 mutation status shapes the immune phenotype of prostate cancerMaximilian Jenzer, Peter Keß, Cathleen Nientiedt, et al.
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK+ non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Pageof 12